Skip to main content
letter
. 2016 May;101(5):e196–e199. doi: 10.3324/haematol.2015.139329

Figure 1.

Figure 1.

Kaplan-Meier estimates of (A) overall survival (OS) and (B) progression-free survival (PFS) of the 39 patients included in the study. (C) Duration of remission (DoR) of the 21 patients who obtained complete (CR) or partial (PR) responses at the end of therapy.